Minerva Neurosciences (NASDAQ:NERV) Now Covered by StockNews.com

StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research note issued to investors on Monday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating and issued a $5.00 price target on shares of Minerva Neurosciences in a report on Wednesday, February 26th.

Minerva Neurosciences Stock Up 8.4 %

NASDAQ:NERV opened at $1.68 on Monday. The business’s 50 day moving average is $2.04 and its two-hundred day moving average is $2.32. Minerva Neurosciences has a 52 week low of $1.42 and a 52 week high of $3.69. The company has a market cap of $11.75 million, a PE ratio of -3.82 and a beta of 0.10.

Minerva Neurosciences (NASDAQ:NERV) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.49. As a group, sell-side analysts expect that Minerva Neurosciences will post -0.3 EPS for the current fiscal year.

Institutional Trading of Minerva Neurosciences

An institutional investor recently raised its position in Minerva Neurosciences stock. Citadel Advisors LLC increased its stake in Minerva Neurosciences, Inc. (NASDAQ:NERV) by 49.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 25,764 shares of the biopharmaceutical company’s stock after purchasing an additional 8,525 shares during the period. Citadel Advisors LLC owned 0.37% of Minerva Neurosciences worth $57,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 34.56% of the company’s stock.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.